Rexahn Pharmaceuticals Inc., of Rockville, Md., reported final data from the dose-escalation segment (stage 1) of a phase Ib/IIa trial showing that in metastatic renal cell carcinoma patients that have previously received multiple therapies, Archexin treatment produced both stable disease (which persisted for up to 383 days) and a reduction in tumor burden.